The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index; 1 of the 7 sources its claims cite were checked for support.
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Open accessAbstract
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In HEK293 cells, knocking down the SDHD subunit of succinate dehydrogenase caused succinate to accumulate and inhibited HIF-α prolyl hydroxylases, stabilizing HIF-1α under normoxic conditions. This provides a mechanism linking TCA cycle dysfunction to vascular tumor phenotypes without VHL mutation.
Key findings
- SDHD-targeting siRNA reduced SDH activity and raised cellular succinate from about 121 µM in controls to about 447 µM (Di3) and 441 µM (Di4); no significant change was seen in DHE oxidation or glutathione redox state, arguing against ROS as the mediator.
- SDH inhibition induced HIF-1α protein under normoxia, produced about a 3-fold increase in HRE-luciferase reporter activity, induced VEGF mRNA to levels comparable with hypoxia or CoCl₂, and increased BNIP3; HIF-2α induction was less pronounced.
- Succinate inhibited PHD activity in vitro in a dose-dependent manner, with an IC50 reported as 0.5 mM, and the membrane-permeable succinate derivative DMS (20 mM, 48 hr) elevated HIF-1α and caused nuclear HIF-1α accumulation under normoxia.
- In SDH-inhibited cells, pVHL binding to the ODD domain was reduced, consistent with decreased ODD hydroxylation; the proposed model is that mitochondrial succinate exits to the cytosol, inhibits PHD, stabilizes HIF-1α, and drives angiogenesis, metastasis, and glycolytic gene expression.
Methods
- HEK293 cells were transfected with scrambled siRNA or SDHD-targeting siRNA (Di3 or Di4); SDH activity was measured by succinate-DCIP oxidoreductase, succinate by GC-MS with deuterated succinic acid as reference, and ROS/redox state by DHE staining and glutathione assays.
- HIF readouts included Western blot for HIF-1α, HIF-2α, and BNIP3, RT-PCR for VEGF, and an HRE-luciferase reporter; PHD activity was assayed in vitro using HA-tagged ODD and cell extracts, and pVHL binding was assessed by immunoprecipitation and far Western blot.
- The study is cell-culture based, with no patient tumor samples or in vivo tumor models described.
Limitations
- Stated in the paper: DMS uptake, conversion to succinate, and metabolism are unknown; different cell types may have different thresholds and mechanisms of HIF activation; succinate may also modulate FIH; and the ROS findings conflict with C. elegans mev-1 observations, possibly due to species or mutation differences.
- Evident from the text: conclusions rely on HEK293 cells and siRNA knockdown rather than SDH-mutant tumors, transfection efficiency was about 50% so populations were mixed, and no in vivo tumor growth or patient tumor validation was performed; elevated succinate in human SDH-mutant tumors is cited as personal communication.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Own result · 3 No full text of the sources · 3 Own interpretation · 1 Supported so far · 1 Own method · 1 No basis given
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since pVHL binding to the ODD domain is dependent on PHD activity (Kaelin, 2002;Safran and Kaelin, 2003)”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
What the sources say
- Not checked — no full text of the sourcecites Kaelin, 2002 source
- Supportedcites Safran and Kaelin, 2003 source
The section “Prolyl hydroxylation earmarks HIF for destruction” (p. 2) says pVHL binds HIF1α only after prolyl residues in its ODD are enzymatically hydroxylated, and identifies PHD proteins as the hydroxylases. The Figure 1 discussion (p. 3) adds that when PHD cannot hydroxylate HIF, pVHL does not recognize it. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“succinate, which accumulates as a result of SDH inhibition, inhibits HIF-␣ prolyl hydroxylases in the cytosol”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cells incubated with 20 mM DMS for 48 hr showed elevated levels of HIF-1␣ under normoxic conditions (Figure 5B).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition”
- Also stated in: § Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition · plain
“there was no detectable difference in DHE oxidation in Di3 and Di4-transfected cells relative to the control (compare Figures 3C and 3D to 3A).”
- Also stated in: § Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition · plain
“no significant difference was observed in the redox state of SDH-inhibited cells as compared to the control scRNAi-transfected cells (Table 1).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In Di3-transfected cells, even though the total GFP-ODD level was higher than in scRNAitransfected cells (Figures 6Aiv and 6Av), the levels of pVHLassociated fluorescence were significantly lower (Figure 6C).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this paper, we show that downregulation of SDH activity results in the accumulation of succinate in cells”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Introduction
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a clear accumulation of HIF-1␣ in the nuclei of cells treated with DMS was observed (Figure 5C)”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no significant difference was observed in the redox state of SDH-inhibited cells as compared to the control scRNAi-transfected cells (Table 1).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there was no detectable difference in DHE oxidation in Di3 and Di4-transfected cells relative to the control (compare Figures 3C and 3D to 3A).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Reactive oxygen species do not play a role in HIF-1␣ induction after SDH inhibition
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“succinate, which accumulates as a result of SDH inhibition, inhibits HIF-␣ prolyl hydroxylases in the cytosol”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Succinate moves freely between the mitochondria and the cytosol via the dicarboxylic acid translocator in the mitochondrial inner membrane and the voltage-dependent anion channel (VDAC/porin) in the mitochondrial outer membrane.
- Rests on an assumption: Succinate is the substrate for SDH in mitochondria and a product of PHD in the cytosol.
- It may state two separate claims as one. 3
- The quote only partly states this claim. 1
- Probably not a substantial claim. 2
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The IC 50 was 5.0ف mM for succinate under these reaction conditions, a level that is attainable in SDH-inhibited cells (Table 1).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Succinate is accumulated in SDH-inhibited cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“leading to stabilization and activation of HIF-1␣.”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Rests on an assumption: Succinate moves freely between the mitochondria and the cytosol via the dicarboxylic acid translocator in the mitochondrial inner membrane and the voltage-dependent anion channel (VDAC/porin) in the mitochondrial outer membrane.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“succinate has been shown to inhibit some ␣-ketoglutarate-dependent oxygenases, including procollagen prolyl hydroxylase and thymine-7-hydroxylase (Holme, 1975;Myllyla et al., 1977).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Introduction
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Actin was used as loading control.”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Experimental procedures Succinic acid quantification by GCMS Plasmids
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The PHD isozymes belong to the Fe 2ϩ and ␣-ketoglutarate-dependent family of dioxygenases that split molecular oxygen to hydroxylate their substrates and, in parallel, oxidize and decarboxylate ␣-ketoglutarate to succinate (Schofield and Zhang, 1999).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Introduction
What the sources say
- Not checked — no full text of the sourcecites Schofield and Zhang, 1999 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“the PHDs utilize ␣-ketoglutarate as a cosubstrate and require ferrous iron (Fe 2ϩ ) and ascorbate as cofactors (Kaelin, 2002;Schofield and Zhang, 1999).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Introduction
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Succinate moves freely between the mitochondria and the cytosol via the dicarboxylic acid translocator in the mitochondrial inner membrane and the voltage-dependent anion channel (VDAC/porin) in the mitochondrial outer membrane.
“Succinate moves freely between the mitochondria and the cytosol via the dicarboxylic acid translocator in the mitochondrial inner membrane and the voltage-dependent anion channel (VDAC/porin) in the mitochondrial outer membrane.”
The paper relies on this without support.
Succinate is the substrate for SDH in mitochondria and a product of PHD in the cytosol.
“succinate, the substrate for SDH in mitochondria and a product of PHD in the cytosol.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In intact cells, this introduces an additional level of complexity, because the lack of enzymatically active CII will result in the accumulation of its substrate succinate due to the poor membrane permeability of this metabolite.27”
From Ubiquinone-binding site mutagenesis reveals the role of mitochondrial complex II in cell death initiation (2015) · cites this paper as [27]
Experimental — accuracy not yet measuredIn the citing paper
“Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1a”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [27]
In the citing paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [27]
In the citing paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [27]
In the citing paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [27]
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Selak et al., 2005
In the citing paper
“Metabolite accumulation in the setting of dysfunctional mitochondria can inhibit VHL-dependent degradation of hypoxia-inducible factor-α (HIF-α) subunits, creating a pseudohypoxic state that mimics VHL loss (14).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [14]
In the citing paper
“The other mechanism by which succinate supports tumorigenesis acts through the inhibition of hypoxia-inducible factor prolyl hydroxylase (PHD). PHD activates the pseudohypoxic response by stabilizing HIF-1α, which is a well-known tumorigenesis enhancer”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [127]
In the citing paper
“TCA cycle dysfunction leads to oncogenesis by regulating signaling pathway and stabilizing HIF1-α (Selak et al., 2005).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Selak et al., 2005
In the citing paper
“Dysregulated SDH activity in the setting of these mutations promotes the accumulation of succinate and mitochondrial reactive oxygen species, activating HIF1α and inducing angiogenesis (Selak et al., 2005).”
From SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways (2013) · cites this paper as Selak et al., 2005
In the citing paper
“H2O2 also can participate in the one-electron reaction with transition metal ions (e.g., Fe2+ bound to organic molecules) to generate various intermediate ferryl species (274, 275), such as Fe(IV) = O•, a powerful oxidizing agent that can lead to lipid oxidation and DNA damage, as discussed in section VI.”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [275]
In the citing paper
“High levels of succinate resulting from loss of complex II function can in turn block HIF1α degradation through inhibition of prolyl hydroxylases.”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [19]
In the citing paper
“Selak et al. showed that disruption of the mitochondrial complex II results in increased HIF1α activity and that this upregulation is channeled through inhibition of prolyl hydroxylase function [19].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [19]
In the citing paper
“Succinate activates HIF-1α in tumours10,26, indicating an important similarity between inflammation and cancer.”
From Succinate is an inflammatory signal that induces IL-1β through HIF-1α (2013) · cites this paper as [10]
In the citing paper
“Succinate can be transported from the mitochondria via the dicarboxylic acid transporter to the cytosol where in excess it impairs PHD activity (by product inhibition) leading to HIF-1α stabilization and activation.”
From Succinate is an inflammatory signal that induces IL-1β through HIF-1α (2013) · cites this paper as [10]
In the citing paper
“Selak et al. reported that complex II deficiency achieved by the suppression of SdhD induces normoxic HIF-1 𝛂 stabilization via the accumulation of succinate without inducing a detectable increase in ROS production (43, 44).”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [43]
In the citing paper
“Decreases in Sdh activity should cause an accumulation of succinate, which can transit to the cytosol through the dicarboxylate carrier. There, it potentially can inhibit PHD and cause HIFα stabilization through a pseudohypoxia pathway that does not require ROS (43, 44).”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [43]
In the citing paper
“We agree that increases in succinate represent an important contribution to the stabilization of HIFα in cells with Sdh inhibition (43).”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [43]
In the citing paper
“PHDs are inactive at low O2 and can be inactivated by the accumulation of TCA metabolites fumarate and succinate, which may occur from mutations in the tumor suppressor genes succinate dehydrogenase subunit B or fumarate hydratase (187, 334, 384).”
From Redox regulation of mitochondrial function (2012) · cites this paper as [384]
In the citing paper
“Loss-of-function mutations in SDH and FH cause a build-up of succinate and fumarate, respectively87. Accordingly, increased levels of succinate and fumarate caused by mutations in these genes can compete with αKG and inhibit activity of HIF hydroxylases and thus induce normoxic HIF1α activity in vitro88,89.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [88]
In the citing paper
“In addition to affecting the activity of chromatin-associated αKG-dependent dioxygenases, succinate and fumarate accumulation can also inhibit αKG-dependent prolyl hydroxylases, leading to stabilization of HIF-1 and concomitant activation of the HIF/hypoxia transcriptional program (184, 185).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [185]
In the citing paper
“However, succinate is also an inhibitor of HIF-1α(213), which has been implicated in the exaggerated production of sFlt-1 and in the pathophysiology of preeclampsia(214, 215)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [213]
In the citing paper
“High levels of succinate and fumarate can inhibit PHD2 activity through product-mediated inhibition of PHD function, leading to HIF-1α protein stabilization under normoxic (20% O2) conditions (100, 101).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [101]
In the citing paper
“Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIF stability, through product inhibition (Selak et al., 2005).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Selak et al., 2005
In the citing paper
“elevated levels of succinate or fumarate can inhibit PHD activity [65, 66]”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [66]
In the citing paper
“Both succinate and fumarate are competitive PHD inhibitors, and the massive accumulation of these metabolites in cells lacking SDH or FH activity elicit a hypoxic response even under oxygen-replete condition (Isaacs et al., 2005; Selak et al., 2005).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Selak et al., 2005
In the citing paper
“Furthermore, both succinate and fumarate aberrantly increase the function of hypoxia inducible factors (HIFs).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Selak et al., 2005
In the citing paper
“It should be noted that hypoxia and ischemia, as well as decreased oxidative phosphorylation, drive succinate accumulation in the mitochondrial matrix26,27.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [27]
In the citing paper
“Succinate inhibits the hydroxylation of HIF-1␣ by EGLN1, resulting in pseudohypoxic HIF-1␣ stabilization under normoxic conditions (10 -12).”
From Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels (2016) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
“without pVHL (i, iii, v) or with pVHL (ii, iv, vi) together with one of the indicated siRNA constructs: scRNAi (i-iv), Di3 (v), or Di4 (vi).”
§ Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-␣ prolyl hydroxylase > Elevation of succinate level following downregulation of SDH leads to PHD inhibition and HIF-1␣ stabilization in cells
“When cells were cotransfected with GFP-ODD, HA-tagged pVHL, and Therefore, it is likely that in SDH-inhibited cells, the HIF-1␣ ODD domain is hydroxylated less efficiently, and consequently the either of the siRNA constructs, higher GFP levels were observed in Di3-and Di4-transfected cells compared to scRNAi-trans-binding of pVHL to GFP-ODD is reduced.”
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 1×
“In particular, elevated levels al., 2001; Jaakkola et al., 2001; Yu et al., 2001).”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“, facilitate HIF-2 (cid:1) degradation in these cells, despite the fact that PHD activity is inhibited. and ascorbate, it undergoes hydroxylation and migrates faster CANCER CELL : JANUARY 2005 on SDS-PAGE (Huang et al., 2002; Ivan et al., 2001).”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333 · cited 1×
“The hydroxylases (HPH1-3 or PHD1-3) (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2002).”
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549 · cited 1×
“The hydroxylases (HPH1-3 or PHD1-3) (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2002).”
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520 · cited 11×
“) and ascorbate as cofactors (Kaelin, 2002; Scho-field and Zhang, 1999).”
BackgroundMethodInfluentialA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500 · cited 1×
“The tumor suppressor p53, which is known to elevate ROS production (Polyak et al., 1997), was used as a positive control.”
MethodOxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000 · cited 1×
“…c oxidase we found that hydrogen peroxide can induce HIF-1 (cid:1) levels as (complex IV), hence allocating more oxygen for PHD activity in was previously described (Chandel et al., 2000) (data not shown), we observed neither ROS generation nor a shift to a the cytosol (Hagen et al., 2003).”
BackgroundAsparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“The transcriptional activity of HIF-(cid:1) is also regulated by hydroxylation of an asparaginyl residue in its C-terminal transactivation domain in a reaction catalyzed by factor inhibiting HIF (FIH) (Hewitson et al., 2002; Lando et al., 2002a,2002b).”
BackgroundLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550
Research works printed but not linked: 1
- Beasley, 2002, Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer, Cancer Res., 62, 2493
Cited by
Sorted by citations
Items 1,201–1,300 of 2,106
Lee, C., Gundem, G., Lee, W., Chen, Y., Cross, J. R., Dong, Y., Redzematovic, A., Mano, R., Wei, E. Y., Cheng, E. H. Y., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00007 · Cited by 24
New insights on the pathogenesis of paraganglioma and pheochromocytoma
Kantorovich, V., & Pacák, K. (2018) · F1000Research · doi:10.12688/f1000research.14568.1 · Cited by 24
A conditional mouse model of complex II deficiency manifesting as Leigh‐like syndrome
Khazal, F. J. A., Holte, M. N., Bolon, B. N., White, T. A., LeBrasseur, N. K., & Maher, L. J., III (2019) · The FASEB Journal · doi:10.1096/fj.201802655rr · Cited by 24
“Current models for tumorigenesis upon SDH loss invoke succinate as an accumulating oncometabolite (19) that poisons dioxygenase enzymes important for gene expression and epigenetic control in certain cell types (16).”
BackgroundAbdel‐Hamid, N. M., Abd‐Elghany, M. I., Nazmy, M., et al. (2012) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-012-0292-8 · Cited by 24
“Several key genetic alterations associated with tumor development have recently been shown to affect glycolysis directly, such as p53 mutation and the activation of hypoxia inducible factor [53, 54].”
BackgroundInhibition of Angiogenesis and HIF-1α Activity by Antimycin A1
Maeda, M., Hasebe, Y., Egawa, K., Shibanuma, M., & Nose, K. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1344 · Cited by 24
Aleyasin, H., Karuppagounder, S. S., Kumar, A., Sleiman, S. F., Basso, M., Ma, T. C., Siddiq, A., Chinta, S. J., Brochier, C., Langley, B. C., et al. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5595 · Cited by 24
A diverse proteome is present and enzymatically active in metabolite extracts
House, R. J., Soper-Hopper, M. T., Vincent, M. P., Ellis, A. E., Capan, C. D., Madaj, Z., Wolfrum, E., Isaguirre, C., Castello, C. D., Johnson, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50128-z · Cited by 32
Branched-chain α-ketoacids aerobically activate HIF1α signalling in vascular cells
Xiao, W., Shrimali, N. M., Vigder, N., Oldham, W. M., Clish, C. B., He, H., Wong, S. J., Wertheim, B. M., Arons, E., Haigis, M. C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01150-4 · Cited by 27
Acute COVID-19 and LongCOVID syndrome – molecular implications for therapeutic strategies - review
Michalak, K. P., Michalak, A. Z., & Brenk-Krakowska, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582783 · Cited by 27
“The positive feedback between HIF-1 a and succinate/fumarate acts as an ampli fi er of this relationship (115) as succinate and fumarate contribute to the stabilization of HIF-1 a , while activation of HIF-1 a leads to an increase in their concentration in mitochondria by blocking PDH, activating…”
Kiss, N. B., Muth, A., Stenman, A., Juhlin, C. C., Geli, J., Bäckdahl, M., Höög, A., Wängberg, B., Nilsson, O., Ahlman, H., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0267 · Cited by 22
“Importantly, the breakdown of the mitochondrial respiratory chain by loss of SDH function leads to accumulation of succinate, which causes inhibition of a-ketoglutaratedependent enzymes (that normally produce succinate as a byproduct; Lee et al. 2005, Selak et al. 2005).”
BackgroundTargeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer
Godel, M., Ortone, G., Anobile, D. P., Pasino, M., Randazzo, G., Riganti, C., & Kopecka, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050762 · Cited by 23
“Moreover, since HIF-1α is activated by succinate, the use of HIF-1α inhibitors has been proposed as an alternative and effective strategy to block the tumor progression driven by succinate [36].”
BackgroundInfluentialImmunometabolites Drive Bacterial Adaptation to the Airway
Tomlinson, K. L., Prince, A. S., & Lung, T. W. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790574 · Cited by 25
“Succinate and ROS stabilize the host transcription factor hypoxia-inducible factor 1a (HIF-1a) by inhibition of prolyl hydroxylase (PHD) in the cytosol (19) (Figure 1).”
BackgroundCasas-Benito, A., Martínez-Herrero, S., & Martínez, A. (2023) · Cancers · doi:10.3390/cancers15102862 · Cited by 26
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 23
Cho, K., Shin, H., Kim, Y.-I., Cho, C., Chun, Y., Kim, T.-Y., & Park, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.02.022 · Cited by 23
“Recently, SDH dysfunction has been a hot issue as an oncogenic event [32].”
BackgroundGenetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 21
“These genes are activated by Hif1α (or Hif2α), which is constantly degraded by the proteosome when oxygen levels are in the normal range (63).”
BackgroundInfluentialLago, C. U., Nowinski, S. M., Rundhaug, J. E., Pfeiffer, M. E., Kiguchi, K., Hirasaka, K., Yang, X., Abramson, E. M., Bratton, S. B., Rho, O., et al. (2012) · Oncogene · doi:10.1038/onc.2011.630 · Cited by 23
Paddenberg, R., Tiefenbach, M., Faulhammer, P., Goldenberg, A., Gries, B., Pfeil, U., Lips, K. S., Piruat, J. I., López‐Barneo, J., SCHERMULY, R. T., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr359 · Cited by 22
Co-Operation between Aneuploidy and Metabolic Changes in Driving Tumorigenesis
Newman, D. L., & Gregory, S. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184611 · Cited by 24
“epigenetic changes to gene expression [26], as well as aberrant stabilization of HIF-1alpha that promotes glycolysis and vascularisation [27] and a range of effects on inflammatory signalling [25].”
BackgroundLückmann, M., Trauelsen, M., Frimurer, T. M., & Schwartz, T. W. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.12.005 · Cited by 23
Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas
Sarkadi, B., Meszaros, K., Krencz, I., Canu, L., Krokker, L., Zakarias, S., Barna, G., Sebestyen, A., Papay, J., Hujber, Z., et al. (2020) · Cancers · doi:10.3390/cancers12030599 · Cited by 23
“The succinate accumulation in SDHx mutant tumors can inhibit the α-ketoglutarate-dependent prolyl hydroxylases, which have an important role in the degradation of HIF1α and HIF2α under normoxia [12].”
Oncogenic alterations of metabolism and the Warburg effect
Kim, J., Gardner, L. B., & Dang, C. V. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.04.001 · Cited by 23
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Wenger, R. H., Camenisch, G., Stiehl, D. P., & Katschinski, D. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649411 · Cited by 21
Yang, Q., Cai, Y., Ma, Q., Xiong, A., Xu, P., Zhang, Z., Xu, J., Zhou, Y., Liu, Z., Zhao, D., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3868 · Cited by 22
Zhang, H.-Y., Shu, Y., Li, Y., Hu, Y., Wu, Z., Li, Z.-P., Deng, Y., Zheng, Z., Zhang, X., Gong, L.-F., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114915 · Cited by 24
Kręgiel, D. (2012) · InTech eBooks · doi:10.5772/48413 · Cited by 25
Zhou, Q., Jiang, L., Qiu, J., Pan, Y., Swanda, R. V., Shi, P., Li, A., & Zhang, X. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.0c01543 · Cited by 21
Self-citationAdvances in paraganglioma–pheochromocytoma cell lines and xenografts
Bayley, J., & Devilee, P. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0434 · Cited by 24
SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma
Bayley, J., Bausch, B., Jansen, J. C., Hensen, E. F., van der Tuin, K., Corssmit, E. P. M., Devilee, P., & Neumann, H. P. H. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107656 · Cited by 23
Connections between metabolism and epigenetic modifications in cancer
Wang, G., & Han, J. J. (2021) · Medical Review · doi:10.1515/mr-2021-0015 · Cited by 27
“Excess succinate or fumarate inhibits HIF prolylhydroxylases, and consequently promotes the stabilization of HIF-1α in normoxic conditions, thereby activating the expression of HIF target genes that can involve in glucose metabolism and angiogenesis [28, 202, 203].”
BackgroundNAD+ salvage governs the immunosuppressive capacity of mesenchymal stem cells
Fang, J., Hou, P., Liu, S., Zuo, M., Liu, Z., Chen, W., Han, Y., Li, Y., Wang, T., Feng, C., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01073-2 · Cited by 23
Ma, C., Zhu, C., Zhang, Y., Yu, M., Song, Y., Chong, Y., Yang, Y., Zhu, C., Jiang, Y., Wang, C., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155266 · Cited by 23
Marzola, M. C., Chondrogiannis, S., Grassetto, G., Rampin, L., Maffione, A. M., Ferretti, A., Opocher, G., Schiavi, F., Colletti, P. M., & Rubello, D. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31829aface · Cited by 22
Hypoxia‐inducible factors – regulation, role and comparative aspects in tumourigenesis
Hansen, A. E., Kristensen, A. T., Law, I. G., Jørgensen, J. T., & Engelholm, S. A. (2010) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2010.00233.x · Cited by 23
Müller, U. (2011) · Neurogenetics · doi:10.1007/s10048-011-0280-y · Cited by 22
“This is accomplished by inhibition of HIF-prolyl-hydroxylase (PHD, HPH or EgIN) that is necessary for degradation of HIF1α [31, 32].”
BackgroundSmestad, J. A., Hamidi, O., Wang, L., Holte, M. N., Khazal, F. J. A., Erber, L. N., Chen, Y., & Maher, L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23639 · Cited by 20
Impact of Sirtuin Enzymes on the Altered Metabolic Phenotype of Malignantly Transformed Cells
Gaál, Z., & Csernoch, L. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00045 · Cited by 22
“These mutations also contribute to the stabilization of HIF1α, due to the inhibition of α-ketoglutarate-dependent prolyl hydroxylase enzyme (37).”
BackgroundNovel Mitochondria-targeted Drugs for Cancer Therapy
Fialová, J. L., Raudenská, M., Jakubek, M., Kejík, Z., Pavel Martasek, E., Babula, P., Matkowski, A., Filipenský, P., & Masařík, M. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201118153242 · Cited by 22
Galmiche, A., & Fueller, J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.012 · Cited by 24
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 22
SDH defective cancers: molecular mechanisms and treatment strategies
Wang, J., Yuan, T., Yang, B. W., He, Q., & Zhu, H. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10022-w · Cited by 24
Arneson‐Wissink, P. C., Hogan, K. A., Ducharme, A. M., Samani, A., Jatoi, A., & Doles, J. D. (2020) · JCSM Rapid Communications · doi:10.1002/rco2.14 · Cited by 21
Hypoxia-inducible factors not only regulate but also are myeloid-cell treatment targets
Kling, L., Schreiber, A., Eckardt, K., & Kettritz, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0820-535r · Cited by 25
Kassa, B., Kumar, R., Mickael, C. S., Sanders, L., Vohwinkel, C. U., Lee, M. H., Gu, S., Poth, J. M., Stenmark, K. R., Zhao, Y., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00351.2020 · Cited by 21
Basic Mechanisms of Immunometabolites in Shaping the Immune Response
Ryan, D. G., Peace, C. G., & Hooftman, A. (2023) · Journal of Innate Immunity · doi:10.1159/000535452 · Cited by 22
“While succinate was a well-characterized oncometabolite in tumours [42], the fi rst report of succinate as a pro-in fl ammatory intracellular signal was made only around a decade ago [43].”
BackgroundComplex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 20
Hussain, I., Husain, Q. M., Baredes, S., Eloy, J. A., Jyung, R. W., & Liu, J. K. (2013) · Journal of neurosurgery · doi:10.3171/2013.10.jns13659 · Cited by 21
Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies
Renella, R., Carnevale, J. C., Schneider, K. A., Hornick, J. L., Rana, H. Q., & Janeway, K. A. (2014) · Familial Cancer · doi:10.1007/s10689-014-9725-4 · Cited by 21
Guo, X., Li, D., Wu, Y., Chen, Y., Zhou, X., Wang, X., Huang, X., Li, X., Yang, H., & Xing, J. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.005 · Cited by 23
McCarty, M. F. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.07.023 · Cited by 22
“(Somewhat surprisingly, an increased concentration of alpha-ketoglutarate does not counteract this effect; however, succinate is a competitive antagonist of alpha-ketoglutarate in PHD2, for which reason alpha-ketoglutarate administration can promote PHD2 activity in rare tumors with succinate dehydrogenase deficiency…”
BackgroundMitochondrial metabolic remodeling in response to genetic and environmental perturbations
Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 22
“This produces a hypermethylator phenotype of the chromatin(67) as well as a pseudohypoxic phenotype through the stabilization of HIF in the presence of oxygen.(68) This has the significant consequence of changing mitochondrial activity to a more ‘hypoxia-like’ state through HIF1 signaling.”
BackgroundLiang, J., Lin, Y., Ouyang, T., Tang, W., Huang, Y., Ye, W., Zhao, J., Wang, Z.-N., & Ma, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i25.3218 · Cited by 20
The RNA helicase DDX5 supports mitochondrial function in small cell lung cancer
Xing, Z., Russon, M. P., Utturkar, S. M., & Tran, E. J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012600 · Cited by 21
“Tumors with succinate dehydrogenase mutations that cause succinate accumulation are highly metastatic and aggressive, displaying decreased expression of genes needed for cellular differentiation and/or stabilizing HIF1a, which promotes cell growth and survival (48, 49).”
BackgroundMa, H., Li, Y., Hou, T., Li, J., Long, Y., Guo, H., Li, L., Xin, M., & Gong, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.624809 · Cited by 20
Controlled power: how biology manages succinate-driven energy release
Mookerjee, S. A., Gerencser, A. A., Watson, M. A., & Brand, M. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20211032 · Cited by 21
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., Anoz‐Carbonell, E., Pacheco‐García, J. L., Medina, M., & Pey, A. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050747 · Cited by 22
Mutational analysis of hypoxia‐related genes HIF1α and CUL2 in common human cancers
Park, S. W., Chung, N. G., Hur, S. Y., Kim, H. S., Yoo, N. J., & Lee, S. H. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02550.x · Cited by 21
“Also, inherited genetic defects in succinate dehydrogenase and fumarate hydratase that are linked to HIF1a metabolism activate HIF1a (19, 20).”
BackgroundZhou, S., Liu, R. R., Yuan, K., Yi, T., Zhao, X., Huang, C., & Wei, Y. (2012) · Mass Spectrometry Reviews · doi:10.1002/mas.21362 · Cited by 21
Cellular Respiration and Carcinogenesis
Sarangarajan, R., & Apte, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3 · Cited by 20
“showed that OXPHOS dysfunction can alter the expression of nuclear genes coding for factors involved in extracellular matrix remodeling in human osteosarcoma cells [28].”
BackgroundInfluentialZhu, P., Liu, Y., Zhang, F., Bai, X., Chen, Z., Shangguan, F., Zhang, B., Zhang, L., Chen, Q., Xie, D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2059 · Cited by 20
Yang, J., Chuang, Y.-C., Tseng, J., Liu, Y., Lai, C.-Y., Lee, A. Y., Huang, C. F., Hong, Y., & Chuang, T. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03094-9 · Cited by 27
“Reactive oxygen species and succinate have been shown to increase the stabilization and activation of hypoxia-inducible factor 1α (HIF-1α) by inactivating prolyl hydroxylases (PHD) [15, 16, 24, 25].”
BackgroundResultInfluentialAmino Acid and Glucose Fermentation Maintain ATP Content in Mouse and Human Malignant Glioma Cells
Lee, D. C., Ta, N. L., Mukherjee, P., Duraj, T., Domin, M. A., Greenwood, B. P., Karmacharya, S., Narain, N. R., Kiebish, M. A., Chinopoulos, C., et al. (2024) · ASN NEURO · doi:10.1080/17590914.2024.2422268 · Cited by 21
“Our data support these findings and show for the first time that glutamine could be fermented for sufficient ATP content in glioma cells.”
InfluentialGut-lung immunometabolic crosstalk in sepsis: from microbiota to respiratory failure
Li, Q., Song, X.-C., Li, K., & Wang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1685044 · Cited by 25
Sarkar, D., Ankolekar, C., Greene, D. W., et al. (2018) · Journal of Food Science and Technology · doi:10.1007/s13197-018-3090-5 · Cited by 20
Bernardo‐Castiñeira, C., Valdés, N., Celada, L., Martínez, A. S. J., Sáenz‐de‐Santa‐María, I., Bayón, G. F., Fernández, A. F., Sierra, M., Fraga, M. F., Astudillo, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01471 · Cited by 20
Khumukcham, S. S., Penugurti, V., Soni, A., Veena, U., Hari, K., Jolly, M. K., Dwivedi, A., Abdul Salam, P. K., Padala, C., Srinivasulu, M., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.002 · Cited by 20
Bai, Y., Liu, Y., Qu, A., Wang, J., Zhao, J., Ke, Q., Chen, X., Pu, F., Wu, L., Xu, P., et al. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.739104 · Cited by 21
Environmental and behavioral regulation of HIF-mitochondria crosstalk
Burtscher, J., Hohenauer, E., Burtscher, M., Millet, G. P., & Egg, M. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.06.015 · Cited by 27
Chen, K., Tan, Z., Liu, L., Liu, B., Zhan, L., Zhu, J., Li, X., Lin, K., Liu, J., Liu, Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.170340 · Cited by 22
“Mutations in 2 important metabolic enzymes, IDH and SDH, have been identified in sarcomas (59–61).”
BackgroundTargeting Mitochondria for Cancer Treatment
Zorova, L. D., Abramicheva, P. A., Andrianova, N. V., Babenko, V. A., Zorov, S. D., Pevzner, I. B., Popkov, V. A., Semenovich, D. S., Yakupova, E. I., Silachev, D. N., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040444 · Cited by 23
Hadrévi, J., Björklund, M., Kosek, E., Hällgren, S., Antti, H., Fahlström, M., & Hellström, F. (2015) · Scientific Reports · doi:10.1038/srep15925 · Cited by 20
Therapies in inborn errors of oxidative metabolism
Schiff, M., Bénit, P., Jacobs, H. T., Vockley, J., & Rustin, P. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.006 · Cited by 21
The metabolic switch and its regulation in cancer cells
Zhou, S., Huang, C., & Wei, Y. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4041-1 · Cited by 21
Nikam, A. P., Patankar, J. V., Lackner, C., Schöck, E., Kratky, D., Zatloukal, K., & Abuja, P. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066094 · Cited by 20
“It has been described recently that efflux of TCA cycle intermediates such as succinate and fumarate into the cytosol can lead to inhibition of several a-ketoglutarate-dependent dioxygenases, including prolyl hydroxylases [37,38].”
BackgroundMitochondrial Signaling in Hypoxia
Lukyanova, L. D. (2013) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2013.32a004 · Cited by 22
“[54-58].”
Merlo, A., Fernández, S. B. D. Q., Sáenz‐de‐Santa‐María, I., Pitiot, A. S., Balbı́n, M., Astudillo, A., Scola, B., Arístegui, M., Quer, M., Suarez, C. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1636 · Cited by 20
Hoekstra, A. S., Addie, R. D., Ras, C., Seifar, R. M., Ruivenkamp, C. A. L., Bruijn, I. H. B., Hes, F. J., Jansen, J. C., Corssmit, E. P. M., Corver, W. E., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw218 · Cited by 19
Potentiating anti-cancer chemotherapeutics and antimicrobials via sugar-mediated strategies
Mullapudi, S. S., Mitra, D., Li, M., Kang, E. T., Chiong, E., & Neoh, K. G. (2020) · Molecular Systems Design & Engineering · doi:10.1039/c9me00175a · Cited by 22
Zhunussova, A., Sen, B., Friedman, L., Tuleukhanov, S. T., Brooks, A. D., Sensenig, R., & Orynbayeva, Z. (2015) · Europe PMC (PubMed Central) · Cited by 20
Owens, K. M., Modica-Napolitano, J. S., & Singh, K. K. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_1 · Cited by 21
Metabolic dysregulation of tricarboxylic acid cycle and oxidative phosphorylation in glioblastoma
Trejo‐Solís, C., Serrano-García, N., Castillo‐Rodríguez, R. A., Robledo‐Cadena, D. X., Jiménez‐Farfán, D., Marín‐Hernández, Á., Silva‐Adaya, D., Rodríguez-Pérez, C. E., & Gallardo‐Pérez, J. C. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0054 · Cited by 20
Kosvyra, A., Karadimitris, A., Papaioannou, M., et al. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108735 · Cited by 19
de Bresser, C. J. M., & de Krijger, R. R. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09830-3 · Cited by 22
Li, M., Li, G., Yu, B., Luo, Y., & Li, Q. (2019) · Shock · doi:10.1097/shk.0000000000001347 · Cited by 18
“Previous studies had indicated that normoxic activation of HIF-1a in cancer involves inhibition or mutation of the metabolic enzyme SDH (18).”
BackgroundSaskői, É., Hujber, Z., Nyírő, G., Likó, I., Mátyási, B., Petővári, G., Mészáros, K. V., Kovács, A., Patthy, L., Supekar, S., et al. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044925 · Cited by 19
“…degradation and active HIF favors pseudohypoxia-driven tumorigenesis through mal-activation of hypoxia-responsive genes such as vascular endothelial growth factor (VEGF; also known as VEGFA) or glucose transporter 1 (GLUT1; also known as SLC2A1) (Pollard et al., 2005; Selak et al., 2005).”
BackgroundSpecific cyprinid HIF isoforms contribute to cellular mitochondrial regulation
Chen, J., Guan, L., Zou, M., He, S., Li, D., & Chi, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-74210-w · Cited by 19
Molecular Mechanisms of Acute Oxygen Sensing by Arterial Chemoreceptor Cells. Role of Hif2α
Ortega‐Sáenz, P., Moreno‐Domínguez, A., Gao, L., & López‐Barneo, J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.614893 · Cited by 21
“…been reported to modulate over 2,000 transcripts, many of them critically involved in numerous pathophysiological processes such as embryogenesis, stem cell fate and differentiation, tissue regeneration, inflammation and cancer, among others (Ratcliffe, 2013; Semenza, 2014; Colgan et al., 2020).”
Backgroundvan Doorn, C. L. R., Schouten, G. K., van Veen, S., Walburg, K. V., Esselink, J. J., Heemskerk, M. T., Vrieling, F., & Ottenhoff, T. H. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739938 · Cited by 18
Zhang, H., D’Alessandro, A., Li, M., Reisz, J. A., Riddle, S. R., Muralidhar, A., Bull, T., Zhao, L., Gerasimovskaya, E. V., & Stenmark, K. R. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107157 · Cited by 21
Gastrointestinal Stromal Tumor – An Evolving Concept
Tornillo, L. (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00043 · Cited by 18
“IGF1R-targeted therapy of wild-type GIST is being investigated in clinical trials (e.g., NCT01560260) (154).”
BackgroundInfluentialZakharchenko, M. V., Zakharchenko, A. V., Khunderyakova, N. V., Tutukina, M. N., Simonova, M. A., Vasilieva, A. A., Romanova, O. I., Fedotcheva, N. I., Litvinova, E. G., Maevsky, E. I., et al. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.07.003 · Cited by 20
Steensel, M. A. M. V., van Geel, M., Badeloe, S., Poblete‐Gutiérrez, P., & Frank, J. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00808.x · Cited by 19
Hua, Y., Ma, Q., Zhang, X., Yao, W., Ji, P., Hu, J., & Wei, Y. (2018) · Biomedical Chromatography · doi:10.1002/bmc.4402 · Cited by 19
Ulaje, S. A., Rojo‐Arreola, L., Lluch-Cota, S. E., Ascencio, F., Cruz‐Hernández, P., & Sicard, M. T. (2019) · Aquaculture Research · doi:10.1111/are.13960 · Cited by 19
Zhang, S., Cao, L., Li, Z., & Qu, D. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.045 · Cited by 20
Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?
Fishbein, L. M. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1184-y · Cited by 19
HIF‑1α regulates A2B adenosine receptor expression in liver cancer cells
Kwon, J. H., Lee, J., Kim, J., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8081 · Cited by 19
“Also the pharmacologic studies with HIF activator or inhibitor treatment implicated HIF-1α-stabilization increases in liver cancer proliferation (25).”
BackgroundLoss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics
Dona, M., Waaijers, S., Richter, S., Eisenhofer, G., Korving, J., Kamel, S. M., Bakkers, J., Rapizzi, E., Rodenburg, R. J., Zethof, J., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0308 · Cited by 21
Determination and Modulation of Prolyl‐4‐Hydroxylase Domain Oxygen Sensor Activity
Wirthner, R., Balamurugan, K., Stiehl, D. P., Barth, S., Spielmann, P., Oehme, F., Flamme, I., Katschinski, D. M., Wenger, R. H., & Camenisch, G. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35003-9 · Cited by 19
“…et al., 2003), transition metals (Hirsilä et al., 2005; Martin et al., 2005), Krebs cycle intermediates (Dalgard et al., 2004; Lu et al., 2005; Selak et al., 2005) and reactive oxygen species (ROS) including NO (BerchnerPfannschmidt et al., 2006; Gerald et al., 2004; Metzen et al., 2003) have…”
BackgroundMillán‐Uclés, Á., Castro, B. D., García‐Flores, P., Báez, A., Pérez‐Simón, J. A., López‐Barneo, J., & Piruat, J. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085528 · Cited by 19
“This change in gene expression seems to be mediated by a ‘‘pseudo-hypoxic’’ response in which Hif1a plays a central regulatory role [11,12,13].”
Background
Metadata
- Authors
- Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E.
- Affiliations
- Cancer Research UK (GB)
- University of Pennsylvania (US)
- University of Strathclyde (GB)
- Corresponding author
- Gottlieb, Eyal
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 7
- Issue
- 1
- Pages
- 77-85
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2057199368
- Cited by
- 2,108
- References
- 47
- Citations by year
- 2026: 110 · 2025: 115 · 2024: 97 · 2023: 97 · 2022: 116 · 2021: 139 · 2020: 128 · 2019: 123 · 2018: 93 · 2017: 107 · 2016: 110 · 2015: 107 · 2014: 108 · 2013: 109 · 2012: 86
- FWCI
- 26.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Beatson Institute for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- succinic acid, succinate dehydrogenase, HIF-1α, prolyl hydroxylase, mitochondrial dysfunction, tumor suppressor proteins, carcinogenesis, VHL, tumor angiogenesis, fumarate hydratase
- MeSH terms
- Animals, Cell Line, Cell Transformation, Neoplastic, Citric Acid Cycle, Enzyme Activation, Humans, Mitochondria, Oncogenes, Procollagen-Proline Dioxygenase, Succinate Dehydrogenase, Transcription Factors, Signal Transduction, Gene Expression Regulation, Enzymologic, Reactive Oxygen Species, Succinic Acid, Tumor Suppressor Proteins, RNA, Small Interfering, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
